Total project cost: £280,000
GBF awarded: £200,000
Status: Refurbishment works complete, outcomes ongoing
Critical investment secured by Enterprise Oxfordshire enabled the refurbishment of key areas of a major biomanufacturing facility in Oxford, supporting its status as a global leader.
The University of Oxford’s Clinical BioManufacturing Facility – located on the Old Road Campus in Headington – is a major leader in the production of vaccines for early phase clinical trials, including the world-renowned Oxford-AstraZeneca Covid-19 vaccine.
The investment has enabled future works to support its expansion moving forward. Through this expansion, the University’s capabilities to potentially increase the UK’s share of the global vaccine and biologics manufacturing market – worth over $1billion – will be enhanced, as well as the facility’s ability to attract and support small businesses operating in the sector to lead their own clinical trials of investigational medicinal products.
Delivery partner: University of Oxford
Please note: This film was created when Enterprise Oxfordshire was trading as OxLEP.
Enable the future expansion of the facility
Creates the potential to increase the UK’s share of the global vaccine and biologics manufacturing market (worth over $1billion)
Speeds up clinical trials of novel biotech products
Products can improve patient outcomes with long term benefits